Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02511132
Title A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gradalis, Inc.

Ewing sarcoma of bone

extraosseous Ewing sarcoma


FANG vaccine

Docetaxel + Gemcitabine

FANG vaccine + Irinotecan + Temozolomide

Age Groups: adult | child | senior
Covered Countries USA

No variant requirements are available.